$QNCX
Quince Therapeutics, Inc. Stock $qncx

$qncx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000166277424000005 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.058M	$3.857M
YoY Change	-55.84%	-8.82%
% of Gross Profit
Research & Development	$4.916M	$4.147M
YoY Change	243.54%	206.5%
% of Gross Profit
Depreciation & Amortization	$86.00K	$44.00K
YoY Change
% of Gross Profit
Operating Expenses	$5.863M	$28.19M
YoY Change	-3.79%	404.87%
Operating Profit	-$5.863M	-$28.19M
YoY Change	-3.79%	404.87%
Interest Expense	$683.0K	$823.0K
YoY Change	-28.85%	1.6%
% of Operating Profit
Other Income/Expense, Net	$150.0K	$91.00K
YoY Change	-169.44%	-185.05%
Pretax Income	-$5.479M	-$27.69M
YoY Change	2.41%	466.32%
Income Tax	$13.00K	$36.00K
% Of Pretax Income
Net Earnings	-$5.492M	-$27.73M
YoY Change	2.64%	467.52%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.13	-$0.64
Diluted Earnings Per Share	-$0.13	-$0.64
COMMON SHARES
Basic Shares Outstanding	43.28M shares	43.22M
Diluted Shares Outstanding	43.16M shares	43.10M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.85M	$59.45M
YoY Change	-41.94%	-30.51%
Cash & Equivalents	$2.675M	$7.890M
Short-Term Investments	$45.17M	$51.56M
Other Short-Term Assets	$55.00K	$79.00K
YoY Change	-40.22%	-44.76%
Inventory
Prepaid Expenses	$565.0K	$443.0K
Receivables
Other Receivables
Total Short-Term Assets	$51.72M	$63.44M
YoY Change	-39.28%	-28.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$208.0K	$246.0K
YoY Change	4060.0%	4000.0%
Goodwill	$0.00	$0.00
YoY Change
Intangibles	$64.53M	$61.79M
YoY Change
Long-Term Investments	$78.00K	$78.00K
YoY Change	-22.0%	-22.0%
Other Assets	$9.506M	$8.798M
YoY Change	9406.0%	8698.0%
Total Long-Term Assets	$74.80M	$71.39M
YoY Change	35017.84%	24688.54%
TOTAL ASSETS
Total Short-Term Assets	$51.72M	$63.44M
Total Long-Term Assets	$74.80M	$71.39M
Total Assets	$126.5M	$134.8M
YoY Change	48.17%	51.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.622M	$2.405M
YoY Change	296.58%	581.3%
Accrued Expenses	$3.803M	$2.916M
YoY Change	106.24%	82.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.425M	$10.32M
YoY Change	140.79%	428.74%
LONG-TERM LIABILITIES
Long-Term Debt	$14.90M	$13.83M
YoY Change
Other Long-Term Liabilities	$643.0K	$609.0K
YoY Change
Total Long-Term Liabilities	$643.0K	$609.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.425M	$10.32M
Total Long-Term Liabilities	$643.0K	$609.0K
Total Liabilities	$81.59M	$87.86M
YoY Change	3521.26%	4401.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$364.0M	-$358.5M
YoY Change	17.12%	17.39%
Common Stock	$405.5M	$404.4M
YoY Change	3.09%	3.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.93M	$46.97M
YoY Change
Total Liabilities & Shareholders Equity	$126.5M	$134.8M
YoY Change	48.17%	51.77%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$5.492M	-$27.73M
YoY Change	2.64%	467.52%
Depreciation, Depletion And Amortization	$86.00K	$44.00K
YoY Change
Cash From Operating Activities	-$7.260M	-$8.739M
YoY Change	50.94%	128.17%
INVESTING ACTIVITIES
Capital Expenditures	$46.00K	$39.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$7.151M	-$4.939M
YoY Change	96.46%	-75.71%
Cash From Investing Activities	$7.105M	-$4.978M
YoY Change	95.73%	-75.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.000M	35.00K
YoY Change	-50100.0%	16.67%
NET CHANGE
Cash From Operating Activities	-7.260M	-8.739M
Cash From Investing Activities	7.105M	-4.978M
Cash From Financing Activities	-5.000M	35.00K
Net Change In Cash	-5.155M	-13.68M
YoY Change	340.6%	-43.28%
FREE CASH FLOW
Cash From Operating Activities	-$7.260M	-$8.739M
Capital Expenditures	$46.00K	$39.00K
Free Cash Flow	-$7.306M	-$8.778M
YoY Change	51.89%	129.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43276606	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43276606	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43096374	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43096374	shares
CY2024Q2	qncx	Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod	35000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1223000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-726000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-12000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-27729000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46968000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	90203000	usd
CY2023Q2	qncx	Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod	27000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1321000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	59000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	160000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4886000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	86884000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	85084000	usd
	qncx	Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod	225000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2497000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1955000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-5000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38878000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46968000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100593000	usd
	qncx	Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod	82000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2803000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	152000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	394000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17140000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	86884000	usd
	us-gaap	Profit Loss ProfitLoss	-38878000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2497000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	84000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
	qncx	Loss On Disposal LossOnDisposal	0	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4765000	usd
	qncx	Increase Decrease In Fair Value Of Borrowings IncreaseDecreaseInFairValueOfBorrowings	803000	usd
	qncx	Non Cash Intangible Impairment Charge NonCashIntangibleImpairmentCharge	17130000	usd
	qncx	Non Cash Intangible Impairment Charge NonCashIntangibleImpairmentCharge	5900000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1266000	usd
	qncx	Change In Deferred Tax Liabilities Due To Acquisition ChangeInDeferredTaxLiabilitiesDueToAcquisition	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2042000	usd
	qncx	Right Of Use Assets Operating Leases And Operating Lease Liabilities RightOfUseAssetsOperatingLeasesAndOperatingLeaseLiabilities	181000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	118000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	401000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-287000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17092000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	85721000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	50131000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	89735000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	35394000	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	90000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	78000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	136000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3936000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14783000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	225000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	82000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	225000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12862000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21929000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20752000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44579000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7890000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22650000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	227000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	70000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358500000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	59400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company’s consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with business combinations including associated intangible assets and goodwill, contingent consideration, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets, including goodwill; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company’s estimates.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	17100000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	17100000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	58794000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	62471000	usd
CY2024Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	13834000	usd
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	76305000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	73538000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	57706000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	13429000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	71135000	usd
	qncx	Weighted Average Remaining Contractual Maturities Of Available For Sale Securities WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities	P6M
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58809000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	58794000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	58794000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	73548000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73538000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73538000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	443000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	365000	usd
CY2024Q2	qncx	Prepaid Insurance Current PrepaidInsuranceCurrent	282000	usd
CY2023Q4	qncx	Prepaid Insurance Current PrepaidInsuranceCurrent	809000	usd
CY2024Q2	qncx	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	2225000	usd
CY2023Q4	qncx	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	133000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	964000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	993000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	79000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	81000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3993000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2381000	usd
CY2024Q2	qncx	Reductions In Research And Development Expense ReductionsInResearchAndDevelopmentExpense	400000	usd
	qncx	Reductions In Research And Development Expense ReductionsInResearchAndDevelopmentExpense	800000	usd
	qncx	Reductions In Research And Development Expense ReductionsInResearchAndDevelopmentExpense	0	usd
CY2023Q2	qncx	Reductions In Research And Development Expense ReductionsInResearchAndDevelopmentExpense	0	usd
CY2024Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	3748000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	3463000	usd
CY2024Q2	qncx	Deferred Tax Assets Long Term Tax Credit Carryforwards Foreign DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign	4965000	usd
CY2023Q4	qncx	Deferred Tax Assets Long Term Tax Credit Carryforwards Foreign DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign	4993000	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	78000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	78000	usd
CY2024Q2	qncx	Assets Held For Sale AssetsHeldForSale	7000	usd
CY2023Q4	qncx	Assets Held For Sale AssetsHeldForSale	10000	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	8798000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	8544000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	566000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	507000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	246000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	234000	usd
CY2024Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1844000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2340000	usd
CY2024Q2	qncx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	500000	usd
CY2023Q4	qncx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	564000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	200000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	211000	usd
CY2024Q2	qncx	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	94000	usd
CY2023Q4	qncx	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	64000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	278000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	257000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2916000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3436000	usd
CY2023Q4	qncx	Accrued Severance AccruedSeverance	341000	usd
CY2022Q4	qncx	Accrued Severance AccruedSeverance	0	usd
	qncx	Accrued Severance Incurred AccruedSeveranceIncurred	0	usd
	qncx	Accrued Severance Incurred AccruedSeveranceIncurred	268000	usd
	qncx	Accrued Severance Paid AccruedSeverancePaid	251000	usd
	qncx	Accrued Severance Paid AccruedSeverancePaid	268000	usd
CY2024Q2	qncx	Accrued Severance AccruedSeverance	90000	usd
CY2023Q2	qncx	Accrued Severance AccruedSeverance	0	usd
CY2023Q2	us-gaap	Severance Costs1 SeveranceCosts1	300000	usd
CY2023Q2	us-gaap	Other Restructuring Costs OtherRestructuringCosts	100000	usd
CY2023Q3	us-gaap	Severance Costs1 SeveranceCosts1	500000	usd
	qncx	Severance Costs Recognized SeveranceCostsRecognized	300000	usd
CY2023Q3	qncx	Additional Cash Bonus Severance Percentage AdditionalCashBonusSeverancePercentage	1
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.50
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	554000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	385000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	64000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	453000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	321000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	547000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	385000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0909
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0795
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	68000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	136000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	133000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	127000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	203000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	667000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	120000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	547000	usd
CY2024Q2	qncx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans	3	plan
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1223000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1321000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2497000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2803000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10714000	usd
CY2024Q2	qncx	Long Term Debt Maturities Repayments Of Principal Year Three And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalYearThreeAndThereafter	0	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10714000	usd
CY2024Q2	qncx	Debt Instrument Imputed Interest DebtInstrumentImputedInterest	3120000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	13834000	usd
CY2024Q2	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	36000.0	usd
	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	67000.0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-27729000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4886000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38878000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17140000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43096374	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43096374	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35917592	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35917592	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43053351	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43053351	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35886568	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35886568	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10093914	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7648305	shares
CY2023Q4	us-gaap	Share Price SharePrice	0.989
CY2023Q4	qncx	Nda Acceptance Under Contingent Consideration NDAAcceptanceUnderContingentConsideration	25000000.0	usd
CY2023Q4	qncx	Probability Discount Rate Of Each Milestone ProbabilityDiscountRateOfEachMilestone	0.15
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	1000	usd
CY2023	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	19000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	450000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	475000	usd
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	17100000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	17100000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	17625000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	17130000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-495000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	0	usd

Files In Submission

Name	View Source	Status
0001662774-24-000005-index-headers.html	Edgar Link	pending
0001662774-24-000005-index.html	Edgar Link	pending
0001662774-24-000005.txt	Edgar Link	pending
0001662774-24-000005-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qncx-20240630.htm	Edgar Link	pending
qncx-20240630.xsd	Edgar Link	pending
qncx-20240630xexx311.htm	Edgar Link	pending
qncx-20240630xexx312.htm	Edgar Link	pending
qncx-20240630xexx321.htm	Edgar Link	pending
qncx-20240630xexx322.htm	Edgar Link	pending
qncx-20240630_g1.jpg	Edgar Link	pending
qncx-20240630_g2.jpg	Edgar Link	pending
qncx-20240630_g3.jpg	Edgar Link	pending
qncx-20240630_g4.jpg	Edgar Link	pending
qncx-20240630_g5.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qncx-20240630_cal.xml	Edgar Link	unprocessable
qncx-20240630_def.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
qncx-20240630_lab.xml	Edgar Link	unprocessable
qncx-20240630_pre.xml	Edgar Link	unprocessable
qncx-20240630_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QNCX
Quince Therapeutics, Inc. Stock $qncx

2024 Q3 Form 10-Q Financial Statement

#000166277424000005 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QNCX Quince Therapeutics, Inc. Stock $qncx

2024 Q3 Form 10-Q Financial Statement

#000166277424000005 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QNCX
Quince Therapeutics, Inc. Stock $qncx